The FDA pulled menopause hormone therapy's boxed warning. Prescribing was already rising.

On February 12, 2026, the FDA approved revised labels for the first six menopausal hormone therapy products, removing statements about cardiovascular disease, breast cancer, and probable dementia from the boxed warning — the most prominent safety text a US drug label carries [s1].

The six were Bijuva (Mayne Pharma), Divigel (Vertical Pharmaceuticals), Cenestin (Teva Pharmaceuticals), Enjuvia (Duramed Pharmaceuticals), Prometrium (Abbott Laboratories), and Estring (Pfizer) [s1]. The boxed warning for endometrial cancer remains on systemic estrogen-alone products for women with a uterus [s1][s2].

This implements an action announced on November 10, 2025, when the Department of Health and Human Services and the FDA said they would revise safety labeling across menopausal hormone therapy [s2][s3]. The February approvals are the first batch, not the whole set.

"This decision reflects our commitment to follow the science wherever it leads and to correct course when the evidence demands it," said Robert F. Kennedy Jr., Secretary of Health and Human Services [s1]. FDA Commissioner Marty Makary, MD, MPH, said the change would help women "make well-informed medical decisions" [s1].

What the warning was, and what it did

The boxed warnings trace to the Women's Health Initiative, launched in 1991, whose results released in 2002 suggested that systemic hormone therapy raised risks of cardiovascular problems, breast cancer, endometrial cancer, and possibly dementia [s3]. The effect on practice was immediate and enormous: hormone therapy use among postmenopausal women fell from roughly 27% in 1999 to 5% by March 2020 [s3].

The core critique of the old labeling is not that the trial was wrong but that its findings were applied indiscriminately. A warning derived from one formulation, in a population whose average age was well past menopause onset, ended up printed on every estrogen product including low-dose vaginal preparations [s2][s3].

Updated labeling now emphasizes timing — initiating therapy before age 60 or within 10 years of menopause onset — as the frame for weighing benefit against risk [s2][s4].

What the supporting societies actually said

The most useful document on this is not a press release. On January 25, 2026, Biology of Sex Differences published a joint statement from authors affiliated with the Organization for the Study of Sex Differences and the Society for Women's Health Research supporting the FDA action [s4]. It is worth reading because the same authors who endorse the change also enumerate the distinctions the simplified label does not draw.

Their supporting evidence: reanalysis of the Women's Health Initiative found women initiating therapy at ages 50 to 59 "experienced reductions in myocardial infarction, death, and overall adverse events" relative to older initiators [s4]. A Danish randomized trial of 1,006 women found that after 10 years, hormone therapy was associated with significantly lower risk of death, heart failure, or myocardial infarction, with no increase in cancer or stroke [s4]. In the ELITE trial, oral estradiol started within six years of menopause slowed progression of carotid intima-media thickness, while later initiation did not [s4].

Their caveats, which are the part that matters:

Formulation is not interchangeable. The Women's Health Initiative used conjugated equine estrogen; contemporary preparations using 17β-estradiol show different safety profiles [s4]. A label that has been simplified across a product class does not encode that difference.

Route matters. Oral hormone therapy carries higher thromboembolism risk than transdermal formulations, which the authors note show better cardiovascular outcomes [s4].

Breast cancer risk does not follow the timing hypothesis. This is the most important complication in the document. The authors cite an individual participant meta-analysis finding that "relative risks for breast cancer in current systemic HT users were greater if therapy was begun before or soon after menopause" [s4]. Early initiation, which improves the cardiovascular picture, does not correspondingly improve the breast cancer picture — it may run the other way.

Underlying tissue health may determine direction of effect. The authors invoke the "healthy cell bias" concept: estrogen may be protective in healthy tissue but "detrimental when disease pathology is already present" [s4].

The Society of Gynecologic Oncology's response makes a related point: decisions "must remain individualized and providers must continue to counsel patients about potential risks, particularly in the context of hormone-sensitive cancers" [s2].

None of these caveats amount to opposition. They amount to a claim that the removal of a too-broad warning does not by itself create a correctly calibrated one.

Prescribing was moving before the label did

An analysis published by Truveta on April 9, 2026, using prescription and dispensing data from 2018 through February 2026, found estrogen-based hormone therapy prescribing rising well ahead of the February label approvals [s5].

The overall rate went from 11.5 per 1,000 women in January 2018 to 23.5 per 1,000 in February 2026, a 104.8% increase [s5]. Between July 2025 and February 2026 — a window that brackets the FDA expert panel and the November announcement — the rate rose from 19.7 to 23.5 per 1,000, a 19.1% increase [s5].

By February 2026, prescribing rates by age were 49.0 per 1,000 women aged 45 to 54, 41.6 per 1,000 aged 55 to 64, 22.1 per 1,000 aged 65 to 74, 15.1 per 1,000 aged 75 and older, and 7.2 per 1,000 aged 18 to 44 [s5]. Since 2018, the increase was 184.2% among women aged 45 to 54 and 95.3% among women aged 55 to 64 [s5].

The analysis carries real limits, which Truveta states: it did not capture all menopausal treatments, could not confirm menopausal status, could not verify whether prescriptions were filled, and may miss or delay dispensing records when no healthcare encounter occurs [s5]. It is also drawn from one health-system data network rather than the full national picture.

The direction, though, is unambiguous, and the timing is instructive. The prescribing shift began before the labels changed. Clinicians and patients were already moving on the reinterpreted evidence; the label change ratified a shift rather than initiating one.

What to watch

How many of the remaining products get approved label revisions, and whether the language is consistent across formulations and routes — the societies' central concern is that a uniform label obscures non-uniform risk [s4]. Whether prescribing growth accelerates, plateaus, or concentrates in the age bands where the timing evidence is strongest. And whether breast cancer incidence data in the coming years reflects the meta-analytic signal the supporting societies flagged [s4].

This article describes a regulatory action and published evidence. It is informational only, is not medical advice, and does not recommend for or against hormone therapy for any person.

Sources

• [s1] FDA Approves Drug Labeling Changes to 6 Menopausal Hormone Therapy Products, Pharmacy Times, 2026-02-12.
• [s2] FDA Removes Black-Box Warnings on Hormone Replacement Therapy, Society of Gynecologic Oncology, 2025-11-20.
• [s3] FDA removes menopause hormone therapy black box warnings, Harvard Health Publishing, 2025-11-13.
• [s4] Cunningham, Galea, Goulmamine et al., Advancing evidence-based regulation: OSSD and SWHR support FDA action on menopausal hormone therapy and encourage broader sex-informed drug label updates, Biology of Sex Differences, 2026-01-25.
• [s5] Estrogen-based hormone replacement therapy use is rising, Truveta, 2026-04-09.